Divis Laboratories Ltd

Divis Laboratories Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 14 July 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with the latest comprehensive analysis.

Divis Laboratories Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 4 August 2026. Despite a modest intraday decline, the stock’s robust trading volumes and recent upgrade in its Mojo Grade to ‘Buy’ underscore growing institutional confidence and sustained investor interest in this large-cap pharmaceutical leader.

Rs 8,000 put options on Divis Laboratories Ltd attracted 1,896 contracts on 4 August 2026, signalling notable activity just below the current stock price of Rs 8,286. This surge in put trading comes as the stock trades within 3.23% of its 52-week high, raising questions about whether the options market is signalling protection, bearish positioning, or a bullish stance through put writing.

The Sensex slipped 0.75% on 3 Aug 2026, yet Divis Laboratories Ltd surged 3.91%, touching a fresh 52-week and all-time high of Rs 8417.25. That 3.16-percentage-point outperformance over the benchmark index signals a distinctly stock-specific strength rather than a market-wide rally.

On 3 Aug 2026, Divis Laboratories Ltd witnessed significant call option activity, with 10,939 contracts traded at the Rs 8,400 strike price, precisely matching the stock’s closing price of Rs 8,400. This synchrony between the options strike and the underlying price highlights a strong directional bet on near-term price movement, supported by a 3.91% gain in the cash market on the same day.

Rs 8,000 put options on Divis Laboratories Ltd attracted 4,128 contracts on 3 Aug 2026, signalling notable activity at a strike price 4.6% below the current market price of Rs 8,380. This surge in put volume comes amid a five-day rally that has lifted the stock by 8.66%, raising questions about whether this is a protective hedge or a bearish wager.

Divis Laboratories Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value, reflecting heightened investor interest and institutional participation. The stock’s recent upgrade from a Hold to a Buy grade by MarketsMOJO, coupled with strong volume and value turnover, underscores its growing appeal amid a volatile market backdrop.

Divis Laboratories Ltd, a large-cap leader in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. This development comes alongside the stock hitting a fresh 52-week high and sustained gains over the past week, underscoring a bullish sentiment despite some intraday volatility.

With a decisive surge to Rs 8417.25 on 3 Aug 2026, Divis Laboratories Ltd has reached a fresh 52-week and all-time high, marking a significant milestone in its price momentum. This rally reflects a confluence of strong technical signals and sustained upward price action over the past several sessions.

Divis Laboratories Ltd commenced trading on 3 August 2026 with a notable gap up, opening 3.28% higher than the previous close and reaching a fresh 52-week and all-time high of Rs 8,417.25. This strong start reflects sustained positive momentum in the pharmaceuticals sector, with the stock outperforming its peers and broader market indices.

Divi's Laboratories Ltd., one of India's leading active pharmaceutical ingredient (API) manufacturers, delivered an exceptional first quarter for FY27, posting a net profit of ₹902.00 crores—a remarkable 65.50% surge year-on-year and 20.11% quarter-on-quarter growth. The stellar performance propelled the stock to ₹8,056.65 on July 31, 2026, gaining 2.76% on the day and touching a fresh 52-week high of ₹8,087.00, reflecting robust investor confidence in the company's operational momentum.

The Sensex edged up 0.13% on 31 Jul 2026, while Divis Laboratories Ltd surged 3.06%, touching a new 52-week and all-time high of Rs 8086.55. This 2.05 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a stock-specific strength rather than a broad market rally.

With a decisive surge to Rs 8,086.55 on 31 Jul 2026, Divis Laboratories Ltd has reached a new 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum.

With a decisive break above its previous peaks, Divis Laboratories Ltd has surged to a new 52-week high of Rs 7,886.55 on 30 Jul 2026, marking a significant milestone in its price momentum. This advance comes amid a sustained four-day rally that has delivered nearly 8% returns, underscoring the stock’s robust technical positioning despite a broadly flat Sensex.

Divis Laboratories Ltd, a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and shifting investor sentiment. The stock hit a new 52-week high of Rs 7,787.5 on 29 Jul 2026, outperforming its sector peers and signalling robust bullish positioning among traders.

Divis Laboratories Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The pharmaceutical giant’s stock has outperformed its sector peers, hitting a fresh 52-week high and attracting increased investor participation, reflecting growing confidence in its near-term prospects.

Divis Laboratories Ltd (DIVISLAB) has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical giant’s stock hit a new 52-week high of Rs 7,744 on 29 Jul 2026, supported by robust volume and sustained buying interest, reflecting growing bullish sentiment among traders and investors alike.